Global Influenza Market Surges Amid Diagnostic Innovation
BOSTON, July 15, 2025 /PRNewswire/ — According to the latest study from BCC Research, 'The Global Influenza Market' is expected to grow from $9.0 billion in 2024 to $12.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2024 to 2029.
This report offers a well-rounded analysis of the global influenza market, covering both historical and current trends. It examines the disease burden, vaccine coverage, and market dynamics across the major regions of North America, Europe, and Asia-Pacific. The market is segmented into vaccines (inactivated and live-attenuated), therapeutics, and diagnostics (rapid and conventional tests). It also highlights leading products, clinical trials, new approvals, and emerging technologies. Additionally, the report profiles major companies and outlines their strategies, while providing growth forecasts and opportunities for each product segment in major regions.
This report is particularly relevant today because public health systems and healthcare providers need to prepare for a potential rise in influenza cases. It helps forecast how many people could need to seek medical care, what quantity of drugs or vaccines will be needed, and which resources such as hospital beds or antivirals might be stretched. For pharmaceutical companies, the report is crucial for identifying areas with strong demand and adjusting their production or distribution strategies accordingly to ensure the timely and efficient delivery of flu vaccines and treatments.
The factors driving the market's growth include:
Faster Testing Technologies: New rapid tests and molecular tools help detect flu viruses quickly and accurately. This allows doctors to treat patients sooner and helps prevent the spread of the virus, boosting demand for diagnostics.
Government Support: Governments are funding research and speeding up approvals for new flu treatments and tests. This support encourages innovation and helps bring new products to market faster.
More Vaccine Awareness: People are more aware of the importance of flu shots, especially after recent global health events. Public campaigns and easier access to vaccines have led to higher vaccination rates.
Request a sample copy of the global influenza market report.
Report Synopsis
Report Metric
Details
Base year considered
2023
Forecast period considered
2024-2029
Base year market size
$8.4 billion
Market size forecast
$12.8 billion
Growth rate
CAGR of 7.2% for the forecast period of 2024-2029
Segments covered
Vaccines, Therapeutics, Diagnostics, and Region
Regions covered
North America, Asia-Pacific, Europe, Rest of the World (includes South America, and the Middle East and Africa)
Countries covered
U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Japan, India, China, Australia,
Market drivers
• Development of rapid tests and molecular technologies.
• Government support and funding for novel therapies and diagnosis.
• Rising public awareness of the need for flu vaccines.
Interesting facts:
GSK Begins Early Flu Vaccine Distribution: Ahead of the 2024–2025 flu season, GSK plc has started shipping its trivalent influenza vaccines across the U.S. This rollout follows the FDA's approval of the lot release and licensing, ensuring timely availability at pharmacies and healthcare facilities.
Sanofi's Dual Vaccine Candidates Fast-Tracked: In December 2024, the FDA granted Fast Track designation to two of Sanofi's combination vaccine candidates designed to protect individuals 50 and older from influenza and COVID-19. These candidates merge two already approved vaccines, each proven effective and well-tolerated in clinical trials.
FluMist, the First Self-Administered Flu Vaccine Approved in the U.S.: In a groundbreaking move, the FDA approved FluMist in 2024 as the only self-administered influenza vaccine available in the U.S. Adults up to age 49 can now use this needle-free nasal spray on their own, while parents or caregivers can administer it to children 2 to 17. The approval was based on a comprehensive submission, including a usability study confirming that adults could safely administer the vaccine to themselves or others within the eligible age range.
Emerging startups
Ansun BioPharma
Virolock Technologies
Vaxart
The report addresses the following questions:
What is the projected size and growth rate of the market?–The global influenza market was valued at $8.4 billion in 2023 and is expected to reach $12.8 billion by the end of 2029. The market is expected to grow at a CAGR of 7.2% from 2024 to 2029.
What factors are driving the growth of the market?– Factors that are driving the market's growth are the development of rapid tests and molecular technologies, government support and funding for novel therapies and diagnosis, and rising public awareness about flu vaccines.
Which market segments are covered in the report?– The market size for influenza is categorized into three product segments: Vaccines, Therapeutics, and Diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. The diagnostics, market is divided into rapid tests and conventional lab tests.
Which product segment will be dominant through 2029?– Vaccines will be the dominant market segment through 2029.
Which region has the highest market share?–The North American market for influenza was valued at $4.2 billion in 2023 and is projected to reach $6.3 billion in 2029, at a CAGR of 7.3% during the forecast period.
Market leaders include:
ABBOTT
ASTRAZENECA
BECTON DICKINSON
BIOCRYST PHARMACEUTICALS INC.
CSL
DAIICHI SANKYO CO. LTD.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC.
HOLOGIC INC.
QUIDELORTHO CORP.
SANOFI
SEKISUI DIAGNOSTICS
THERMO FISHER SCIENTIFIC INC.
VIATRIS INC.
Related reports:
Global Markets for Vaccine Technologies: This report provides an in-depth look at the human vaccine industry, focusing on key trends, market drivers and restraints, and the impact of new technologies and competition. It covers vaccine types, including pneumococcal, HPV, MMR, and influenza, but excludes animal vaccines. The study also examines R&D spending, product launches, and strategic moves like mergers, acquisitions and collaborations. It offers insights for stakeholders such as manufacturers, researchers, healthcare providers, and government agencies, with detailed regional analysis to support market expansion efforts.
Purchase a copy of the report direct from BCC Research.
For further information on any of these reports or to make a purchase, contact info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
Contact Us
Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@bccresearch.comPhone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo – https://mma.prnewswire.com/media/2183242/5416385/BCC_Research_Logo.jpg
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 2023 Independent ProSense® study by Professor Hisanori Kawamoto demonstrating 0% breast cancer local recurrence wins Best of Breast Cancer Award Leading US Breast Surgeon, Dr. Richard Fine, presented data from IceCure's ICE3 study & discussed other recent publications on breast cancer cryoablation CAESAREA, Israel, July 25, 2025 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society's Conference (the 'Conference') which took place earlier this month in Tokyo. 'We believe ProSense® can make a significant impact on improving breast cancer outcomes in Japan by providing women with a minimally invasive option. This year's Conference was highly productive as we engaged with breast surgeons, thought leaders, and industry participants,' stated Eyal Shamir, IceCure's Chief Executive Officer. 'Working with Terumo Corporation in Japan, the country's largest medical device company, we anticipate strong commercial adoption upon regulatory approval for breast cancer, especially given the strong data coming from independent Japanese studies.' IceCure, a sponsor of the Conference, hosted a cryoablation-focused luncheon on Friday, July 11, 2025, led by Professor Takayuki Kinoshita, Division of Breast Surgery, NHO Tokyo Medical Center, with presentations made by: Professor Eisuke Fukuma, who has performed over 600 breast cryoablation procedures, the majority of which were conducted with ProSense®, presented the latest data from his ongoing activity to treat breast cancer at Kameda Medical Center. Professor Fukuma's presentation included the following: From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. Dr. Richard Fine of West Cancer Center & Research Institute in the U.S., and a clinical investigator of IceCure's successfully completed ICE3 breast cancer clinical study, presented findings from the ICE3 study as well as data from independent studies of ProSense® in breast cancer. The Conference gave the Best of Breast Cancer award to an independent study published in the journal Breast Cancer titled 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan'. This study was led by Professor Hisanori Kawamoto, M.D., Ph.D. from the Department of Breast Surgery, Breast and Imaging Center at St. Marianna University School of Medicine in Japan and reported zero (0%) breast cancer local recurrence 5 years following treatment with ProSense®. Dr. Kawamoto commented, 'This is a very important study in Japan, where we are experiencing an upward trend in breast cancer cases, especially among women in their late 40s to their early 60s. These are women who often are at very active stages of their life and therefore there is a growing demand for treatment options that minimize the chance of, or even avoid, hospitalization, in addition to resulting in favorable clinical and cosmetic outcomes. We are very pleased with these results and are hopeful that ProSense® may become a favored option in Japan upon regulatory approval for early-stage breast cancer.' Terumo Corporation is expected to submit an application to the Pharmaceuticals and Medical Devices Agency ('PMDA') of Japan for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. About ProSense®The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors. About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that ProSense® can make a significant impact on improving breast cancer outcomes in Japan; the Company's anticipation of strong commercial adoption upon regulatory approval of ProSense® for breast cancer; the belief of the importance of 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan;' and that Terumo Corporation is expected to submit a PMDA application for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. References and links to websites have been provided in this press release as a convenience, and the information contained on such websites is not incorporated by reference herein. IR Contact: Email: investors@ Michael Polyviou Phone: 732-232-6914 Logo – View original content:
Malaysian Reserve
12 hours ago
- Malaysian Reserve
NAMI Statement on Executive Order Targeting Homelessness and Criminalizing Mental Illness
ARLINGTON, Va., July 25, 2025 /PRNewswire/ — Yesterday, the White House released a new Executive Order, 'Ending Crime and Disorder on America's Streets,' which directs federal agencies to make it easier to involuntarily treat people with serious mental illnesses as part of a bid to address homelessness across the United States. While addressing the nationwide homelessness crisis is urgent and necessary, yesterday's executive order promoting institutionalization of people with mental illness raises grave concerns for NAMI and our community. NAMI's Chief Executive Officer Daniel H. Gillison, Jr. said: 'Mental illness is not a crime, and people with mental illness deserve to be treated as human beings, with dignity and respect. While we agree that homelessness is an urgent crisis in our country, to truly address the systemic causes of this crisis, we should be pouring resources into treatment to improve early access to care and investing in supportive housing and other wrap-around services. It's always ideal – and best – for an individual to engage in their own treatment. Yet, too many NAMI families know that isn't always possible. Unfortunately, yesterday's order concerningly focuses broadly on institutionalization and not on real solutions that we know work in helping people lead better lives.' NAMI believes that in the rare instances where voluntary engagement in treatment is not possible, involuntary commitment should be used only as a last resort and only when it is believed to be in the best interests of the individual. While it is unclear how the executive order will be carried out since state law governs the process of involuntary civil commitment, the order also urges moving away from a 'housing first' approach, which has been successful in helping individuals stay connected to treatment and reduce homelessness. While NAMI is troubled by the overall order, it does include a direction to federal agencies to support crisis response services and prioritize funding for mental health and drug courts – strategies that NAMI supports. This executive order comes at a time when significant cuts are being made to mental health services nationwide. Earlier this month, Congress passed legislation that will drastically cut Medicaid and Supplemental Nutrition Assistance Program (SNAP) benefits, impacting millions of Americans. The Administration has rescinded more than $1 billion in grants from the Substance Abuse and Mental Health Services Administration (SAMHSA), with more cuts proposed for the next fiscal year. These changes will result in far too many people being unable to get the treatment they need. When that happens, more people will be arrested, incarcerated, land in emergency rooms, lose their connection to family and community, and ultimately become homeless. NAMI's Chief Advocacy Officer Hannah Wesolowski said: 'Rather than providing access to critical mental health services, this executive order appears to prioritize coercive tactics to move people who are homeless out of the public eye. This does nothing to address the root causes of homelessness, runs a high risk of exacerbating the homelessness crisis, and is not the way to address our mental health needs. People with mental illness deserve better.' For more information on the public policies that NAMI supports, visit
Malaysian Reserve
a day ago
- Malaysian Reserve
Informal caregivers in Singapore seen as undertrained and overwhelmed
Despite nearly all professional caregivers agreeing that informal caregivers can help bridge the demand of caregiving in Singapore to a certain extent (30% large, 45% moderate, 23% small extent), only a quarter of professionals (25%) say that informal caregivers today are 'somewhat capable' of providing necessary care, with none believing they are 'very capable'. Around four in five (79%) professional caregivers say that informal caregivers are either 'minimally trained' or not 'trained at all' in caregiving; with all professionals agreeing (47% strongly agree, 53% agree) that informal caregivers should receive formal training, especially in skills such as basic emergency response (92%), proper lifting and transfer techniques (90%), recognising condition-specific warning signs and symptoms (88%). Nearly half of professional caregivers (47%) perceive that informal caregivers feel undervalued by society, employers, or even their own families, with a lack of respite care (92%), sleep deprivation (90%), and financial strain (85%) among the top personal challenges faced by informal caregivers. Singapore, July 25, 2025 /PRNewswire/ — Amidst the growing pressures of a super-aged society, Singapore's healthcare sector is experiencing a surge in caregiving demand. While all professional caregivers agree that informal caregivers, such as family members, foreign domestic workers, and volunteers, can help alleviate the demand of caregiving to a certain extent (30% large, 45% moderate, 23% small extent), there are concerns about their capability to provide effective care. Notably, a quarter of respondents (25%) consider informal caregivers only 'somewhat capable', with none believing that they are 'very capable'. This is further compounded by the widespread belief among professional caregivers that informal caregivers are undertrained (77% minimally trained, 2% not trained at all). Consequently, all of them agree (47% strongly agree, 53% agree) that informal caregivers should receive formal training. Essential skills identified by the professionals include basic emergency response (92%), proper lifting and transfer techniques (90%), recognising condition-specific warning signs and symptoms (88%), while important soft skills include decision-making (92%), adaptability (84%), and communication (83%). These are some of the key findings from NTUC LearningHub's Industry Insights Report 2025 on Caregiving, which investigates how professional caregivers, such as those working in the healthcare and social service sectors, perceive informal caregivers who provide support to individuals in need of care at home. Based on a survey of 200 professional caregivers, the report also explores the potential gaps in the caregiving landscape and the implications of evolving healthcare needs on informal caregivers. Additionally, the majority of professional caregivers (77%) also reveal that informal caregivers have little to no awareness of available resources and support services. The most common obstacles to providing effective care include a lack of medical and nursing knowledge (90%), time management (85%), and lack of access to proper equipment or assistive devices (81%). All professional caregivers agree (59% strongly agree, 41% agree) that there is an increasing demand for trained caregivers in Singapore, primarily driven by the ageing population and rising prevalence of chronic illnesses. In response to this growing need, all professional caregivers agree (30% large extent, 49% moderate extent, 22% small extent) that the adoption of assistive technologies has also helped to reduce the burden on informal caregivers, with the most helpful tools identified being mobility aids (97%), emergency response devices (92%) and smart home monitoring systems (82%). However, key barriers to adoption include a lack of training or guidance in effectively using assistive technology (91%), high cost of assistive technologies (91%), and technical complexity of using/setting up assistive tools (89%). At the same time, nearly half of professional caregivers (47%) believe that informal caregivers feel undervalued by society, employers, or even their families as they face personal challenges such as a lack of respite care (92%), sleep deprivation (90%) and financial strain (85%). Commenting on the report's findings, Mr Tay Ee Learn, Assistant Chief Executive Officer and Chief Sector Skills Officer, NTUC LearningHub, says, 'Demand for caregiving support is rising as Singapore's ageing population and the growing prevalence of chronic illnesses lead to longer-term and more complex care needs. Beyond professional caregivers, informal caregivers are quietly but surely cementing their role as key contributors in the care economy, providing invaluable day-to-day care. It is therefore important that they are given access to formal training and relevant resources as they often take on complex caregiving responsibilities without prior experience or professional guidance. With proper training and support, informal caregivers can be empowered to deliver safer, more effective and quality care for their loved ones without compromising their personal well-being. Ultimately, formal training also leads to certifications, providing opportunities for informal caregivers to become professionals in the healthcare sector.' To download the Industry Insights Report 2025 on Caregiving, please visit To find out more about the courses, training, and grants, please contact NTUC LearningHub at About NTUC LearningHub NTUC LearningHub is the leading Continuing Education and Training provider in Singapore which aims to transform the lifelong employability of working people. Since our corporatisation in 2004, we have been working with employers and individual learners to provide learning solutions in areas such as Infocomm Technology, Generative AI & Cloud, Healthcare, Retail & Food Services, Employability & Literacy, Business Excellence, Workplace Safety & Health, Security, Human Resources & Coaching and Foreign Workers Training. To date, NTUC LearningHub has helped over 34,000 organisations and achieved more than 3.2 million training places across more than 1,000 courses with a pool of about 1,000 certified trainers. As a Total Learning Solutions provider to organisations, we also forge partnerships to offer a wide range of relevant end-to-end training. Besides in-person training, we also offer instructor-led virtual live classes (VLCs) and asynchronous online learning. The NTUC LearningHub Learning eXperience Platform (LXP) — a one-stop online learning platform — offers timely, bite-sized and quality content for learners to upskill anytime and anywhere. Beyond learning, LXP also serves as a platform for jobs and skills development for both workers and companies. For more information, visit
